Axovant Sciences Ltd. (NYSE:AXON)‘s stock had its “outperform” rating reiterated by Cowen and Company in a research note issued to investors on Wednesday. They currently have a $30.00 target price on the biotechnology company’s stock. Cowen and Company’s price target suggests a potential upside of 25.00% from the stock’s previous close.

A number of other equities research analysts also recently issued reports on AXON. Oppenheimer Holdings, Inc. lifted their price target on shares of Axovant Sciences from $26.00 to $30.00 and gave the company an “outperform” rating in a research report on Wednesday, June 14th. CIBC lifted their price target on shares of Axovant Sciences from $26.00 to $30.00 and gave the company an “outperform” rating in a research report on Wednesday, June 14th. Jefferies Group LLC reiterated a “buy” rating and set a $31.00 price target on shares of Axovant Sciences in a research report on Friday, June 9th. Zacks Investment Research upgraded shares of Axovant Sciences from a “sell” rating to a “hold” rating in a research report on Thursday, March 9th. Finally, Piper Jaffray Companies reiterated an “overweight” rating and set a $32.00 price target on shares of Axovant Sciences in a research report on Wednesday, April 12th. One analyst has rated the stock with a sell rating, one has given a hold rating and ten have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $27.68.

Analyst Recommendations for Axovant Sciences (NYSE:AXON)

Axovant Sciences (NYSE AXON) opened at 24.00 on Wednesday. The firm’s 50 day moving average price is $22.43 and its 200-day moving average price is $16.56. The firm’s market cap is $2.58 billion. Axovant Sciences has a one year low of $11.01 and a one year high of $25.18.

Axovant Sciences (NYSE:AXON) last posted its quarterly earnings results on Tuesday, June 13th. The biotechnology company reported ($0.53) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.51) by $0.02. Equities analysts predict that Axovant Sciences will post ($2.11) EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Cowen and Company Reiterates “Outperform” Rating for Axovant Sciences Ltd. (AXON)” was originally published by Daily Political and is the sole property of of Daily Political. If you are viewing this story on another publication, it was illegally copied and republished in violation of US & international trademark & copyright law. The original version of this story can be read at https://www.dailypolitical.com/2017/06/23/cowen-and-company-reiterates-outperform-rating-for-axovant-sciences-ltd-axon.html.

In related news, insider David Hung acquired 539,375 shares of the stock in a transaction dated Monday, April 17th. The stock was bought at an average cost of $18.54 per share, with a total value of $10,000,012.50. Following the purchase, the insider now directly owns 539,375 shares of the company’s stock, valued at $10,000,012.50. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director W Anthony Vernon acquired 53,937 shares of the stock in a transaction dated Monday, April 17th. The shares were bought at an average cost of $18.54 per share, with a total value of $999,991.98. Following the completion of the purchase, the director now directly owns 53,937 shares in the company, valued at $999,991.98. The disclosure for this purchase can be found here. Insiders own 3.10% of the company’s stock.

Several hedge funds have recently made changes to their positions in AXON. Bank of America Corp DE boosted its stake in shares of Axovant Sciences by 38.9% in the first quarter. Bank of America Corp DE now owns 7,396 shares of the biotechnology company’s stock valued at $111,000 after buying an additional 2,072 shares in the last quarter. AQR Capital Management LLC bought a new stake in shares of Axovant Sciences during the fourth quarter valued at about $139,000. Oppenheimer & Co. Inc. bought a new stake in shares of Axovant Sciences during the first quarter valued at about $219,000. American International Group Inc. boosted its stake in shares of Axovant Sciences by 7.1% in the first quarter. American International Group Inc. now owns 15,052 shares of the biotechnology company’s stock valued at $225,000 after buying an additional 998 shares in the last quarter. Finally, Wells Fargo & Company MN boosted its stake in shares of Axovant Sciences by 34.3% in the first quarter. Wells Fargo & Company MN now owns 22,435 shares of the biotechnology company’s stock valued at $335,000 after buying an additional 5,733 shares in the last quarter.

About Axovant Sciences

Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.

Receive News & Ratings for Axovant Sciences Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.